1. Search Result
Search Result
Results for "

MLN

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Fluorescent Dye

2

Peptides

5

Inhibitory Antibodies

2

Natural
Products

38

Recombinant Proteins

2

Isotope-Labeled Compounds

16

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-70062
    Pevonedistat
    Maximum Cited Publications
    212 Publications Verification

    MLN4924

    NEDD8-activating Enzyme Apoptosis Cancer
    Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice .
    Pevonedistat
  • HY-10971
    Alisertib
    70+ Cited Publications

    MLN 8237

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib
  • HY-100487
    TAK-243
    80+ Cited Publications

    MLN7243

    E1/E2/E3 Enzyme NF-κB Apoptosis Cancer
    TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis .
    TAK-243
  • HY-13328
    Sapanisertib
    50+ Cited Publications

    INK-128; MLN0128; TAK-228

    mTOR Autophagy Cancer
    Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib
  • HY-10453
    Ixazomib
    20+ Cited Publications

    MLN2238

    Proteasome Autophagy Cancer
    Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
    Ixazomib
  • HY-15246
    Tovorafenib
    5+ Cited Publications

    TAK-580; MLN 2480; BIIB-024

    Raf Cancer
    Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of pan-Raf kinase. Tovorafenib can be used for the study of glioma .
    Tovorafenib
  • HY-P9911
    Vedolizumab
    3 Publications Verification

    Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002

    Integrin Inflammation/Immunology Cancer
    Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
    Vedolizumab
  • HY-111373
    RapaLink-1
    10+ Cited Publications

    mTOR Autophagy Cancer
    RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
    RapaLink-1
  • HY-19414
    MLN-4760
    20+ Cited Publications

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).
    MLN-4760
  • HY-10180
    MLN8054
    5+ Cited Publications

    Aurora Kinase Cancer
    MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
    MLN8054
  • HY-10452
    Ixazomib citrate
    5+ Cited Publications

    MLN9708

    Proteasome Autophagy Cancer
    Ixazomib citrate (MLN9708) is a selective, orally active, second-generation proteasome inhibitor. Ixazomib citrate can be used for the study of a broad range of human malignancies .
    Ixazomib citrate
  • HY-128586
    TAS4464
    5+ Cited Publications

    Apoptosis Carbonic Anhydrase NEDD8-activating Enzyme Cancer
    TAS4464 is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 has a wide selcetive window, without obvious toxicity. TAS4464 can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
    TAS4464
  • HY-15473
    MLN120B
    25+ Cited Publications

    ML120B

    IKK Cancer
    MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
    MLN120B
  • HY-10484
    Pevonedistat hydrochloride
    Maximum Cited Publications
    212 Publications Verification

    MLN4924 hydrochloride

    NEDD8-activating Enzyme Apoptosis Cancer
    Pevonedistat (MLN4924) hydrochloride is a potent and selective NEDD8-activating enzyme (NAE) inhibitor, with an IC50 of 4.7 nM. Pevonedistat hydrochloride induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat hydrochloride suppresses the growth of human tumour xenografts in mice .
    Pevonedistat hydrochloride
  • HY-N6746

    NSC 186

    Bacterial Fungal Endogenous Metabolite Apoptosis Infection Neurological Disease Cancer
    Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
    Citrinin
  • HY-15155
    MLN0905
    5 Publications Verification

    Polo-like Kinase (PLK) Cancer
    MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer .
    MLN0905
  • HY-P99781

    MLN-1202

    CCR Inflammation/Immunology Cancer
    Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Plozalizumab
  • HY-10202
    Tandutinib
    5 Publications Verification

    MLN518; CT53518

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib
  • HY-12285

    MLN1117; INK1117; TAK-117

    PI3K Cancer
    Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.
    Serabelisib
  • HY-128586A
    TAS4464 hydrochloride
    5+ Cited Publications

    NEDD8-activating Enzyme Carbonic Anhydrase Apoptosis Cancer
    TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 hydrochloride against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 hydrochloride targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 hydrochloride exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 hydrochloride has a wide therapeutic window, without obvious toxicity. TAS4464 hydrochloride can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
    TAS4464 hydrochloride
  • HY-123763

    CCR Inflammation/Immunology
    MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx .
    MLN3126
  • HY-P99662

    MLN0264; TAK-264

    Antibody-Drug Conjugates (ADCs) Guanylate Cyclase Apoptosis Cancer
    Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .
    Indusatumab vedotin
  • HY-10202A
    Tandutinib hydrochloride
    5 Publications Verification

    MLN518 hydrochloride; CT53518 hydrochloride

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride
  • HY-19414A

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    (R)-MLN-4760, the R-enantiomer of MLN-4760, is an ACE2 inhibitor, with an IC50 of 8.4 μM. (R)-MLN-4760 is the less active isomer .
    (R)-MLN-4760
  • HY-10971A

    MLN 8237 sodium

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib sodium
  • HY-P991360

    MLN2704 antibody

    PSMA Cancer
    MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .
    MLN 591
  • HY-15155R

    Polo-like Kinase (PLK) Cancer
    MLN0905 (Standard) is the analytical standard of MLN0905. This product is intended for research and analytical applications. MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer .
    MLN0905 (Standard)
  • HY-15473A
    MLN120B dihydrochloride
    25+ Cited Publications

    ML120B dihydrochloride

    IKK Inflammation/Immunology Cancer
    MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
    MLN120B dihydrochloride
  • HY-10453R

    MLN2238 (Standard)

    Reference Standards Proteasome Autophagy Cancer
    Ixazomib (Standard) is the analytical standard of Ixazomib. This product is intended for research and analytical applications. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
    Ixazomib (Standard)
  • HY-70062R

    MLN4924 (Standard)

    NEDD8-activating Enzyme Apoptosis Reference Standards Cancer
    Pevonedistat (Standard) is the analytical standard of Pevonedistat. This product is intended for research and analytical applications. Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice .
    Pevonedistat (Standard)
  • HY-10202AR

    MLN518 hydrochloride (Standard); CT53518 hydrochloride (Standard)

    Reference Standards FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (hydrochloride) (Standard) is the analytical standard of Tandutinib (hydrochloride). This product is intended for research and analytical applications. Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride (Standard)
  • HY-10202R

    MLN518 (Standard); CT53518 (Standard)

    Reference Standards FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (Standard) is the analytical standard of Tandutinib. This product is intended for research and analytical applications. Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib (Standard)
  • HY-10202B

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (MLN518) sulfate is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib sulfate can be used for acute myelogenous leukemia (AML) . Tandutinib sulfate has the ability to cross the blood-brain barrier .
    Tandutinib sulfate
  • HY-156401

    PROTACs Epigenetic Reader Domain Cancer
    BRD9 c-1 (Compound 13-7) is a PROTAC BRD9 degrader . BRD9 Degrader-1 has a micromolar binding affinity for BRD9 and a nanomolar affinity for the BRD9-VCB ternary complex. BRD9 Degrader-1 induces BRD9 proteasome degradation in HEK293T cells, which can be reversed by MLN4924 (HY-70062). (Blue: VH032-cyclopropane-F (HY-125905); Black: linker (HY-W763939); Pink: HY-168695) .
    BRD9 Degrader-1
  • HY-108090

    IKK Inflammation/Immunology
    MLN-0415 is an IKKβ inhibitor. MLN-0415 is commonly used in the study of inflammatory diseases such as arthritis .
    MLN-0415
  • HY-10180R

    Reference Standards Aurora Kinase Cancer
    MLN8054 (Standard) is the analytical standard of MLN8054. This product is intended for research and analytical applications. MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
    MLN8054 (Standard)
  • HY-10180A

    Aurora Kinase Cancer
    MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy .
    MLN8054 sodium
  • HY-RS08498

    Small Interfering RNA (siRNA) Others

    MLN Human Pre-designed siRNA Set A contains three designed siRNAs for MLN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MLN Human Pre-designed siRNA Set A
    MLN Human Pre-designed siRNA Set A
  • HY-RS23083

    Small Interfering RNA (siRNA) Others

    Mln Rat Pre-designed siRNA Set A contains three designed siRNAs for Mln gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mln Rat Pre-designed siRNA Set A
    Mln Rat Pre-designed siRNA Set A
  • HY-10971R

    MLN 8237 (Standard)

    Aurora Kinase Autophagy Apoptosis Reference Standards Cancer
    Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib (Standard)
  • HY-123143

    MLN576

    Topoisomerase Cancer
    XR11576 (MLN576) is an orally active inhibitor of topoisomerase I and II. XR11576 shows cytotoxicity against human and murine tumor cell lines (IC50: 6-47 nM) .
    XR11576
  • HY-P6008

    MLN peptide

    Calcium Channel Cardiovascular Disease
    Myoregulin (MLN peptide) is a member of the regulin family. Myoregulin regulates muscle performance by modulating intracellular calcium handling. Myoregulin interactes directly with sarcoplasmic reticulum Ca 2+-ATPase (SERCA) and impedinf Ca 2+ uptake into the sarcoplasmic reticulum .
    Myoregulin
  • HY-P6008A

    MLN peptide TFA

    Calcium Channel Cardiovascular Disease
    Myoregulin (MLN peptide) TFA is a member of the regulin family. Myoregulin TFA regulates muscle performance by modulating intracellular calcium handling. Myoregulin TFA interactes directly with sarcoplasmic reticulum Ca 2+-ATPase (SERCA) and impedinf Ca 2+ uptake into the sarcoplasmic reticulum .
    Myoregulin TFA
  • HY-13328R

    INK-128 (Standard); MLN0128 (Standard); TAK-228 (Standard)

    mTOR Autophagy Reference Standards Cancer
    Sapanisertib (Standard) is the analytical standard of Sapanisertib. This product is intended for research and analytical applications. Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib (Standard)
  • HY-RS08654

    Small Interfering RNA (siRNA) Others

    MRLN Human Pre-designed siRNA Set A contains three designed siRNAs for MRLN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MRLN Human Pre-designed siRNA Set A
    MRLN Human Pre-designed siRNA Set A
  • HY-N6746R

    NSC 186 (Standard)

    Reference Standards Bacterial Fungal Endogenous Metabolite Apoptosis Infection Neurological Disease Cancer
    Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
    Citrinin (Standard)
  • HY-W748328

    Isotope-Labeled Compounds Autophagy Proteasome Cancer
    Ixazomib- 13C2, 15N is 13C and 15N labeled Ixazomib. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM) .
    Ixazomib-13C2,15N
  • HY-P991604

    YFC51.1; LDP-01

    Integrin Inflammation/Immunology
    MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
    MLN2201
  • HY-100487R

    MLN7243 (Standard)

    E1/E2/E3 Enzyme Reference Standards NF-κB Apoptosis Cancer
    TAK-243 (Standard) is the analytical standard of TAK-243 (HY-100487). This product is intended for research and analytical applications. TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis .
    TAK-243 (Standard)
  • HY-10452R

    MLN9708 (Standard)

    Proteasome Reference Standards Autophagy Cancer
    Ixazomib citrate (Standard) is the analytical standard of Ixazomib citrate (HY-10452). This product is intended for research and analytical applications. Ixazomib citrate (MLN9708) is a selective, orally active, second-generation proteasome inhibitor. Ixazomib citrate can be used for the study of a broad range of human malignancies .
    Ixazomib citrate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: